AIRPanc - Ph2 Randomized Study Evaluating Patients with advanced Pancreatic Ductal Adenocarcinoma

The purpose of this study is to combine standard radiation therapy with drugs that stimulate the body's immune system against cancer cells (by targeting the protein PD-1), while adding drugs which also target the pathway that the tumor uses to evade the immune system (the CD73 and A2a/b pathways).The main goal of this study is to find out if study treatment with zimberelimab (an antibody which binds the protein PD-1) and stereotactic body radiation therapy (SBRT) alone or in combination with quemliclustat (a drug which blocks CD73), with or without etrumadenant (a drug which blocks the A2a/b) given before surgery is safe and if it can further increase the immune response against the tumor.